Table 3.
Multivariable Hazard Ratiosa for Post-diagnosis Cruciferous Vegetable Intake in Association with Recurrence and Total Mortality stratified by ER status, stage, and tamoxifen therapy, After Breast Cancer Pooling Project (n=11,390)
| Cruciferous Vegetable intake | Recurrence
|
Total Mortality
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ER+ | ER− | ER+ | ER− | |||||||||
|
|
|
|||||||||||
| Events | HR | (95% CI) | Events | HR | (95% CI) | Events | HR | (95% CI) | Events | HR | (95% CI) | |
|
|
|
|||||||||||
| Study-specific quartiles (g/day)b | ||||||||||||
| Q1 | 252 | 1.00 | (reference) | 76 | 1.00 | (reference) | 332 | 1.00 | (reference) | 111 | 1.00 | (reference) |
| Q2 | 254 | 0.99 | (0.83–1.18) | 93 | 1.28 | (0.94–1.74) | 311 | 0.98 | (0.84–1.15) | 106 | 1.00 | (0.76–1.31) |
| Q3 | 248 | 0.95 | (0.80–1.13) | 89 | 1.15 | (0.84–1.57) | 305 | 0.96 | (0.82–1.12) | 99 | 0.89 | (0.67–1.17) |
| Q4 | 281 | 1.05 | (0.88–1.25) | 90 | 1.26 | (0.92–1.72) | 299 | 0.93 | (0.79–1.09) | 112 | 1.11 | (0.84–1.45) |
| Ptrend | 0.65 | 0.27 | 0.35 | 0.13 | ||||||||
| Pinteraction | 0.77 | 0.53 | ||||||||||
| Stage I–II | Stage III | Stage I–II | Stage III | |||||||||
|
|
||||||||||||
| Study-specific quartiles (g/day) | ||||||||||||
| Q1 | 234 | 1.00 | (reference) | 102 | 1.00 | (reference) | 331 | 1.00 | (reference) | 123 | 1.00 | (reference) |
| Q2 | 259 | 1.11 | (0.93–1.33) | 98 | 1.02 | (0.77–1.36) | 316 | 1.05 | (0.89–1.22) | 111 | 0.95 | (0.73–1.23) |
| Q3 | 252 | 1.02 | (0.85–1.22) | 95 | 0.99 | (0.75–1.33) | 289 | 0.92 | (0.79–1.08) | 130 | 1.10 | (0.85–1.41) |
| Q4 | 274 | 1.14 | (0.95–1.36) | 107 | 1.05 | (0.79–1.39) | 304 | 1.02 | (0.87–1.20) | 121 | 0.94 | (0.73–1.22) |
| Ptrend | 0.28 | 0.82 | 0.60 | 0.72 | ||||||||
| Pinteraction | 0.44 | 0.76 | ||||||||||
| Tamoxifen | No Tamoxifen | Tamoxifen | No Tamoxifen | |||||||||
|
|
|
|||||||||||
| Study-specific quartiles (g/day)c | ||||||||||||
| Q1 | 203 | 1.00 | (reference) | 47 | 1.00 | (reference) | 256 | 1.00 | (reference) | 69 | 1.00 | (reference) |
| Q2 | 192 | 0.93 | (0.76–1.13) | 59 | 1.24 | (0.84–1.83) | 241 | 0.97 | (0.81–1.15) | 62 | 0.95 | (0.67–1.35) |
| Q3 | 197 | 0.94 | (0.77–1.15) | 50 | 1.01 | (0.68–1.52) | 228 | 0.92 | (0.77–1.11) | 71 | 1.10 | (0.78–1.53) |
| Q4 | 213 | 1.02 | (0.84–1.24) | 67 | 1.19 | (0.80–1.75) | 225 | 0.91 | (0.76–1.10) | 73 | 1.04 | (0.74–1.47) |
| Ptrend | 0.76 | 0.78 | 0.30 | 0.87 | ||||||||
| Pinteraction | 0.53 | 0.28 | ||||||||||
HRs were from delayed entry Cox proportional hazards regression models adjusted for age at diagnosis, ER/PR status (when applicable), TNM stage (when applicable), surgery, chemotherapy, radiotherapy, hormonal therapy (when applicable), smoking, BMI, exercise, menopausal status, race/ethnicity, and education. Study was included as a stratification variable.
Analyses stratified by ER status exclude 320 women missing ER status.
Among women with ER+ cancer (n=8,257), exclude women missing tamoxifen therapy information (n=38).